Abstract:

Objective To explore the effect of lenvatinib, programmed death-1 (PD-1) inhibitor combined with transcatheter arterial chemoembolization in the treatment of patients with advanced liver cancer. Method 40 patients with advanced liver cancer in Gaozhou People's Hospital from July 2022 to May 2024 were selected and divided into two groups by double-blind method, 20 cases in each group. The control group was treated with transcatheter arterial chemoembolization, while the observation group was treated with combination therapy of lenvatinib and PD-1 inhibitor on the basis of the control group. The clinical efficacy, liver related indicators and adverse reactions of the two groups were analyzed and compared. Result After treatment, the effective rate of the observation group was 75%, higher than that of the control group (40%), the difference was significant (P ＜ 0.05). There was no significant difference in alanine aminotransferase, total bilirubin, aspartate aminotransferase and alpha fetoprotein levels between the two groups before and after treatment (P ＞ 0.05). After treatment, the level of alpha fetoprotein in the observation group was significantly lower than that in the control group (P ＜ 0.001). After treatment, the incidence of rash and diarrhea in the observation group was significantly higher than that in the control group (P ＜ 0.05), but there was no significant difference in the incidence of gastrointestinal bleeding, hypertension and proteinuria between the two groups (P ＞ 0.05). Conclusion Transcatheter arterial chemoembolization combined with lenvatinib and PD-1 inhibitor can improve the treatment effect of patients with advanced liver cancer, reduce the level of alpha fetoprotein, and has high safety.

Key words: Middle and advanced stage liver cancer, Lenvatinib, Programmed death -1 inhibitor, Transcatheter arterial chemoembolization